Mural Oncology’s (MURA) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Mural Oncology (NASDAQ:MURA) in a research note issued to investors on Monday,Benzinga reports. HC Wainwright currently has a $18.00 price target on the stock.

Separately, Raymond James began coverage on Mural Oncology in a report on Friday, October 4th. They issued a “strong-buy” rating and a $18.00 price target on the stock.

Mural Oncology Stock Up 2.8 %

NASDAQ:MURA opened at $3.62 on Monday. The business’s 50 day moving average is $3.36 and its two-hundred day moving average is $3.38. Mural Oncology has a 52 week low of $2.88 and a 52 week high of $17.00. The company has a market cap of $61.68 million and a PE ratio of -0.35.

Mural Oncology (NASDAQ:MURA) last released its earnings results on Tuesday, August 13th. The company reported ($1.86) EPS for the quarter, topping analysts’ consensus estimates of ($1.90) by $0.04. As a group, sell-side analysts expect that Mural Oncology will post -7.59 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Adam D. Cutler sold 7,421 shares of the firm’s stock in a transaction that occurred on Thursday, October 31st. The stock was sold at an average price of $3.41, for a total value of $25,305.61. Following the sale, the chief financial officer now owns 71,438 shares of the company’s stock, valued at approximately $243,603.58. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.06% of the company’s stock.

Institutional Trading of Mural Oncology

Several hedge funds have recently added to or reduced their stakes in the business. Armistice Capital LLC acquired a new position in shares of Mural Oncology during the 2nd quarter valued at $5,300,000. Acadian Asset Management LLC bought a new stake in shares of Mural Oncology in the 2nd quarter worth $998,000. Primecap Management Co. CA bought a new stake in shares of Mural Oncology in the 2nd quarter worth $740,000. Renaissance Technologies LLC bought a new stake in shares of Mural Oncology in the 2nd quarter worth $729,000. Finally, Squarepoint Ops LLC bought a new stake in shares of Mural Oncology in the 2nd quarter worth $526,000. Institutional investors own 80.21% of the company’s stock.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.